Comparison of IPX054, IR Carbidopa-Levodopa, and CR Carbidopa-Levodopa in Subjects With Parkinson's Disease

NCT00279825 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

16

Enrollment

INDUSTRY

Sponsor class

Conditions

Idiopathic Parkinson's Disease

Interventions

DRUG: IPX054 200 mg
DRUG: IPX054 250 mg
DRUG: CD-LD IR
DRUG: CD-LD CR
DRUG: IPX054 200 mg Placebo
DRUG: IPX054 250 mg Placebo
DRUG: CD-LD IR Placebo
DRUG: CD-LD CR Placebo

Sponsor

Impax Laboratories, LLC